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Stereotactic body radiation therapy (SBRT), an option for inoperable stage I non–small-cell lung cancer (NSCLC), 
achieves excellent local control with low toxicity.1 However, 
salvage treatment for post-SBRT local recurrence (post-SBRT-
LR) is often difficult in patients with inoperable disease. We 
report two post-SBRT-LR patients successfully treated with 
salvage SBRT. This report was approved by the institutional 
review board (2014–7).
CASE 1
In 2010, a 72-year-old man, on long-term oxygen therapy 
for emphysema with a history of right NSCLC (T1bN0M0) 
treated with the first SBRT, presented with a new nodule in 
the left upper lobe on follow-up computed tomography (CT). 
A second primary NSCLC (T1aN0M0) was diagnosed patho-
logically and by 18F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET)/CT (the maximum standardized 
uptake value [SUVmax]: 3.3). The second SBRT dose for 
this tumor was 50 Gy in five fractions delivered to the 80% 
isodose (50 Gy/5fr [80%-isodose]). In our follow-up policy, 
CT scans were performed at 1 and 3 months after SBRT and 
thereafter at 3-month intervals. FDG-PET/CT was performed 
annually after SBRT. At 24 months after the second SBRT, the 
tumor showed enlargement and increased uptake (SUVmax: 
6.7) on FDG-PET/CT (Fig. 1). After failed biopsy, the new 
lesion was clinically diagnosed as post-SBRT-LR. Salvage 
SBRT was performed with 60 Gy/5fr (60%-isodose). In treat-
ment planning, we attempted to keep the doses delivered to 
the esophagus and trachea within 25 Gy and to minimize the 
doses for the bronchus, pulmonary artery, and left ventricle as 
low as possible. For the second SBRT, those dose constraints 
above for the sum dose were satisfied, whereas the lung and 
chest wall doses were not restricted. The only posttreatment 
toxicity was an asymptomatic rib fracture. The tumor shrank 
and uptake decreased (SUVmax: 2.4) on FDG-PET/CT at 12 
months after salvage SBRT. At 16 months, he died of bleed-
ing from esophageal varices associated with liver cirrhosis. 
Autopsy revealed no tumor cells in either of the lung lesions.
CASE 2
In 2010, an 89-year-old man presented with a solitary nod-
ule in the right upper lobe on chest radiographs. The tumor 
was clinically diagnosed as primary lung cancer (T1bN0M0) 
based on increased uptake (SUVmax: 9.0) on FDG-PET/CT. 
Tumor biopsy was not performed because of high possibility 
of malignancy, his advanced age, and emphysema. He received 
SBRT with 50 Gy/5fr (80%-isodose). Though the tumor 
shrank temporarily, serial enlargement and increased uptake 
(SUVmax: 4.8) on FDG-PET/CT were evident 10 months 
after SBRT (Fig. 2). Post-SBRT-LR was pathologically con-
firmed to be squamous-cell carcinoma, followed by salvage 
SBRT with 60 Gy/5fr (60%-isodose). The post-SBRT-LR was 
controlled, based on the FDG-PET/CT appearance (SUVmax: 
1.9) at 48 months after salvage SBRT, without toxicity.
DISCUSSION
Salvage SBRT is reportedly beneficial for patients previously 
receiving thoracic irradiation. The biological effective dose 
for α/β=10 (BED10) ≥100 Gy was associated with improved 
outcomes,2 and dose reduction may sacrifice tumor control.3 
However, data as to whether additional high-dose irradiation 
is safe and beneficial for post-SBRT-LR patients are lacking. 
Most post-SBRT-LR patients would have already received 
high BED10 (≥100 Gy) because BED10 ≥100 Gy achieves 
excellent outcomes and is thus typically used for SBRT in 
NSCLC.4 Initial SBRT for our two cases was administered 
using high BED10 (100 Gy to periphery and 140 Gy to center 
of planning target volume). For salvage SBRT, both received 
higher BED10 (132 and 300 Gy), prioritizing tumor control. 
The salvage SBRT was consequently safe and effective in both 
the patients, despite the high cumulative dose for the lung. The 
patient with the tumor adjacent to the chest wall experienced 
no severe toxicity but asymptomatic rib fracture. In contrast, 
salvage SBRT for central lung tumor would be difficult if the 
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dose to the pulmonary artery and bronchus in the pulmonary 
hilum exceed 50 Gy.5
Because post-SBRT-LR is thought to be radioresistant, a 
higher dose than in the initial SBRT will be required. A lower 
isodose level for the planning target volume periphery facili-
tates delivering a higher BED to the tumor without increasing 
that to surrounding normal tissue.6
Our results indicate salvage SBRT for post-SBRT-LR 
in peripheral lung with a higher BED and higher intensity to 
possibly be beneficial and safe, though further careful follow-
up is needed.
Although repeated SBRT are promising, prudent diagno-
sis of a recurrence is necessary. In case 2, post-SBRT-LR was 
clinically diagnosed without pathological confirmation. High 
uptake on FDG-PET/CT does not always reflect a recurrence 
but may be a treatment reaction. A recurrence should be diag-
nosed comprehensively by sequential change of a tumor on CT 
and tumor marker elevation in addition with FDG-PET/CT.
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FIGURE 1.  Case 1: A, 
[18F]-fluorodeoxyglucose-positron 
emission tomography/computed 
tomography (18F-FDG-PET/CT) before 
the initial stereotactic body radiother-
apy (SBRT). The maximum standard-
ized uptake value (SUVmax) was 3.3. 
B, Planning CT with dose distribution 
curves of the initial SBRT. A pre-
scribed dose of 50 Gy was delivered 
in five fractions, with isodose lines 
from outer to inner representing 20, 
30, 40, 50, and 60 Gy. C, 18F-FDG-
PET/CT at 24 months after the initial 
SBRT (SUVmax: 6.7). D, Planning 
CT with dose distribution curves of 
salvage SBRT. A prescribed dose of 
60 Gy was delivered in five fractions, 
with isodose lines from outer to inner 
representing 20, 40, 60, 80, and 90 
Gy. E, 18F-FDG-PET/CT (SUVmax: 3.4) 
and (F) plain CT obtained 12 months 
after salvage SBRT.
FIGURE 2.  Case 2: A, 
[18F]-fluorodeoxyglucose-positron 
emission tomography/computed 
tomography (18F-FDG-PET/CT) before 
the initial stereotactic body radiother-
apy (SBRT). The maximum standard-
ized uptake value (SUVmax) was 9.0. 
B, Planning CT with dose distribution 
curves of the initial SBRT. A pre-
scribed dose of 50 Gy was delivered 
in five fractions, with isodose lines 
from outer to inner representing 20, 
30, 40, 50, and 60 Gy. C, 18F-FDG-
PET/CT at 10 months after the initial 
SBRT (SUVmax: 4.4). D, Planning 
CT with dose distribution curves of 
salvage SBRT. A prescribed dose of 
60 Gy was delivered in five fractions, 
with isodose lines from outer to inner 
representing 20, 40, 60, 80, and 90 
Gy. E, 18F-FDG-PET/CT (SUVmax: 2.1) 
and (F) plain CT obtained 36 months 
after salvage SBRT.
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